Federal Bank Strengthens HNI Relationships in Hyderabad Through Exclusive 'Wealth & Wisdom' Forum

Bhubaneswar, Aug. 7 -- Hyderabad, 07th August 2026: Federal Bank's Wealth Management team hosted an exclusive edition of its flagship 'Wealth & Wisdom' series at Hotel Radisson Blu, Hyderabad, bringin... Read More

Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascimi... Read More

Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with ... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy v... Read More

Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adj... Read More

Singapore Clinical Trial: Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant ... Read More

Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the eff... Read More

Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the eff... Read More

Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate... Read More

• ««
• «
• 1355
• 1356
• 1357
• 1358
• 1359
• 1360
• 1361
• 1362
• 1363
• 1364
• »
• »»